14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $18.05 $25.44 Wednesday, 1st May 2024 PHVS stock ended at $24.57. This is 0.0813% less than the trading day before Tuesday, 30th Apr 2024. During the day the stock fluctuated 8.64% from a day low at $23.16 to a day high of $25.16.
90 days $18.05 $33.00
52 weeks $7.93 $33.00

Historical Pharvaris B.V. prices

Date Open High Low Close Volume
Feb 25, 2021 $37.20 $41.40 $37.20 $40.11 185 585
Feb 24, 2021 $31.88 $38.42 $31.40 $37.00 137 230
Feb 23, 2021 $32.94 $36.23 $27.63 $31.53 69 531
Feb 22, 2021 $34.83 $42.86 $33.20 $34.09 152 452
Feb 19, 2021 $31.19 $37.11 $30.79 $35.91 132 117
Feb 18, 2021 $26.82 $31.53 $26.11 $30.74 170 981
Feb 17, 2021 $25.25 $28.21 $25.25 $26.52 228 022
Feb 16, 2021 $27.26 $28.33 $24.26 $25.25 231 902
Feb 12, 2021 $27.50 $28.20 $25.58 $26.67 170 040
Feb 11, 2021 $29.99 $30.00 $27.11 $27.50 255 657
Feb 10, 2021 $31.00 $32.19 $27.78 $30.00 297 675
Feb 09, 2021 $28.70 $30.49 $27.67 $30.19 228 651
Feb 08, 2021 $28.00 $30.44 $27.60 $28.70 529 624
Feb 05, 2021 $25.00 $30.94 $23.06 $29.00 3 813 903
Click to get the best stock tips daily for free!

About Pharvaris B.V.

Pharvaris B.V. Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical ... PHVS Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT